晶云星空晶云星空

Dr. Xiaoxia Chen Joins Crystal Formulation Services as Chief Technology Officer

Dr. Xiaoxia Chen Joins Crystal Formulation Services as Chief Technology Officer

Time:2022-06-01 Browse:110

Suzhou,June 1, 2022 – Crystal Formulation Services (CFS), a technology-driven oral formulation CDMO and subsidiary of Crystal Pharmatech, today announced the appointment ofDr. Xiaoxia Chen as Chief Technology Officer who will be responsible for AnalyticalR&D Center and Manufacturing Science and Technology Center.  


Dr. Chenis an excellent scientist and a technical leader in the pharmaceutical industry,who brings more than 18 years of oral solid formulation development experiencein large pharma, e.g. Merck, Abbvie. Her broad expertise ranges frompreformulation research, formulation development, to process development andregulatory affairs. Xiaoxiao has been responsible for or supported over 35 newdrug development programs with 7 of which were commercialized.


Dr. Chen is trained as Chemical Engineer with her PhD atUniv. of Texas at Austin, MS and BS bothfrom Tsinghua University, and MS inPharmacometrics from Univ. of Maryland at Baltimore.


e2e416bb9b69dbfdaf8b1faf549cd05

“We are absolutely delighted to have Dr. Chen joiningCrystal Pharmatech. Dr. Chen’s exceptional leadership in drug development fromthe large pharma and biotech, her deep expertise in oral solid formulation, andher innovating excellence in formulation development and manufacturing will addtremendous values to our organization,” said Alex Chen, Chairman and CEO ofCrystal Pharmatech. “At Crystal Formulation Service, as we strive to providebest formulation to our customers, we know that Dr. Chen will help ourcustomers accelerate the drug development and commercialization based CFS’ comprehensivesolutions for formulation development and manufacturing.”


Decheng Ma, CEO of Crystal Formulation Service also showedgreat welcome to his old college classmate, “Nothing excites me more thanstarting a business with my classmate from Tsinghua University. Xiaoxia has avery solid engineering background and made great achievements in the field oforal dosage formulations. Her joining will strengthen CFS’ capabilities ofAnalytical R&D and Manufacturing Science and Technology, enabling us toprovide our customers with high-level formulation services.”


“I’m honored to be part of CFS’ mission to provide oralformulation development and manufacturing services for innovative drug productsglobally,” stated Dr. Chen. “It’s so exciting to work with this young,promising team for pursuit of excellence, as it continuously stands out byproviding efficient, high-quality formulation services.”